Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive ...
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: GlobeNewswire
100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord blood-derived natural killer (cbNK) cells/kg pre-complexed with AFM13 No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observedAffimed to host virtual investor event on December 9th to discuss the results HEIDELBERG, Germany, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced interim clinical results from the investigator-initiated phase 1-2 study at The University of Texas MD Anderson Cancer Center, evaluating cbNK cells pre-complexed with Affimed’s innate cell engager (ICE®) AFM13. As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hod
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Affimed (NASDAQ: AFMD) had its price target raised by analysts at Stifel Nicolaus from $1.00 to $5.00. They now have a "hold" rating on the stock.MarketBeat
- Affimed (NASDAQ: AFMD) had its price target raised by analysts at HC Wainwright to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Affimed Reports 2023 Financial Results and Operational ProgressGlobeNewswire
AFMD
Earnings
- 11/14/23 - Beat
AFMD
Sec Filings
- 3/28/24 - Form 6-K
- 3/28/24 - Form 20-F
- 3/11/24 - Form 6-K
- AFMD's page on the SEC website